Selected article for: "early onset and high proportion"
Author: Zhang, J.; Qu, X.
Title: Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals
  • Cord-id: 70jg65o2
  • Document date: 2020_6_14
    • ID: 70jg65o2
    Snippet: Seroconversion appeared early after COVID-19 onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited
    Document: Seroconversion appeared early after COVID-19 onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited cross-neutralization against SARS-CoV (76.12%), MERS-CoV (17.91%), or both (10.45%). Interestingly, individuals recovered from severe disease (severe group) had nAbs with binding and neutralization titers higher than non-severe group. Severe group appeared a rapid increase of lymphocytes and a high proportion of circulating CXCR3+ Tfh cells. Interestingly, the later were spike-specific and positively correlated with SARS-CoV-2 nAb titers. All subjects had no autoimmunity. Our findings provide novel insights into nAb responses in COVID-19 convalescents and facilitate treatment and vaccine development for SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • acute phase and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase and long course: 1, 2
    • acute phase and low lymphocyte count: 1, 2
    • admission lymphocyte count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • admission lymphocyte count and logistic regression analysis: 1, 2, 3, 4, 5, 6
    • admission lymphocyte count and low admission lymphocyte count: 1, 2, 3, 4, 5
    • admission lymphocyte count and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7
    • admission relate and logistic regression: 1
    • logistic regression analysis and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7
    • logistic regression and long course: 1, 2, 3
    • logistic regression and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12